Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIRALAX vs COLYTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Polyethylene glycol 3350 (PEG 3350) is an osmotic laxative that works by retaining water in the stool through hydrogen bonding, increasing fecal water content and promoting bowel movements.
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
Treatment of occasional constipation,Bowel preparation before colonoscopy (off-label)
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
17 g (1 heaping tablespoon) dissolved in 4–8 oz of water, juice, soda, coffee, or tea, administered orally once daily. Maximum duration of use: 7 days.
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
Not applicable; polyethylene glycol 3350 is minimally absorbed and systemic half-life is not clinically relevant.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
PEG 3350 is not metabolized; it is excreted unchanged in feces.
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
Primarily excreted unchanged in feces (>90% of oral dose); negligible renal elimination (<0.1% recovered in urine).
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
Minimal to no protein binding due to negligible systemic absorption.
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
Not applicable due to negligible absorption; localized to gastrointestinal tract.
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Negligible oral bioavailability (less than 0.01%) as the drug is not absorbed from the gastrointestinal tract.
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
No dosage adjustment required for mild to moderate renal impairment (GFR 30–89 m L/min). For severe renal impairment (GFR <30 m L/min) or dialysis-dependent patients, use with caution due to potential for electrolyte disturbances; consider reduced starting dose (e.g., 8.5 g daily) and monitor for adverse effects.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
No specific guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to potential for altered fluid and electrolyte balance. No dose adjustment recommended but clinical monitoring advised.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Children 6 months to <1 year: 4.25 g (1/4 packet) once daily. Children 1 to <6 years: 8.5 g (1/2 packet) once daily. Children 6 to <12 years: 17 g (1 packet) once daily. Dissolve in 4–8 oz of liquid. Maximum duration: 7 days. Not recommended for children <6 months.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
No specific dose adjustment. Use with caution in patients >65 years due to increased risk of electrolyte imbalance and dehydration. Consider initiating with lower doses (e.g., 8.5 g daily) and ensure adequate fluid intake. Monitor for adverse effects, particularly if using for more than a few days.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
None.
None
Use for constipation lasting more than 2 weeks may indicate a serious condition; consider further evaluation.,Do not use if experiencing nausea, vomiting, abdominal pain, or a sudden change in bowel habits lasting more than 2 weeks.,Allergic reactions including urticaria and rash have been reported.,Risk of electrolyte disturbances with prolonged use or in patients with renal impairment.
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Known hypersensitivity to polyethylene glycol or any component of the formulation,Bowel obstruction or perforation,Toxic colitis or megacolon,Gastrointestinal obstruction or ileus
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
None significant. Mira LAX can be mixed with any food or beverage without affecting absorption or efficacy. However, avoid concurrent use with high-fiber supplements or bulk-forming laxatives to prevent excessive stool volume or gas.
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
MIRALAX (polyethylene glycol 3350) is considered non-teratogenic based on animal studies and human data. No increased risk of congenital malformations has been reported. Risk in all trimesters is minimal due to negligible systemic absorption.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
Polyethylene glycol 3350 is not absorbed systemically following oral administration, thus it is not expected to be excreted into breast milk. M/P ratio is not applicable. Considered compatible with breastfeeding.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
No dose adjustment is required during pregnancy. Pharmacokinetics are not significantly altered due to minimal absorption. Standard adult dosing (17 g powder dissolved in 4-8 oz water) is recommended.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
Mira LAX (polyethylene glycol 3350) is an osmotic laxative that works by drawing water into the bowel, softening stool and increasing frequency of movements. Onset of action is 24-48 hours. It is not absorbed systemically, making it safe for most patients, including those with renal impairment. Avoid in bowel obstruction or perforation. For chronic constipation, titrate dose gradually to avoid bloating. Can be mixed with any beverage (hot or cold) for improved compliance.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
Mix one dose (17g) in 4-8 ounces of liquid (water, juice, coffee, soda) and drink immediately. Do not use with starch-thickened liquids.,Do not exceed 7 days of treatment for acute constipation unless directed by a doctor.,May take 24-48 hours to produce a bowel movement. Do not use if you have abdominal pain, nausea, or vomiting.,Store at room temperature. Do not freeze.,Notify your doctor if you experience rectal bleeding or no bowel movement after 7 days.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIRALAX vs COLYTE, answered by our medical review team.
MIRALAX is a Osmotic Laxative that works by Polyethylene glycol 3350 (PEG 3350) is an osmotic laxative that works by retaining water in the stool through hydrogen bonding, increasing fecal water content and promoting bowel movements.. COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIRALAX and COLYTE depend on the specific clinical indication. These are both Osmotic Laxative agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIRALAX is: 17 g (1 heaping tablespoon) dissolved in 4–8 oz of water, juice, soda, coffee, or tea, administered orally once daily. Maximum duration of use: 7 days.. The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIRALAX and COLYTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIRALAX is classified as Category C. MIRALAX (polyethylene glycol 3350) is considered non-teratogenic based on animal studies and human data. No increased risk of congenital malformations has been reported. Risk in al. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.